ACM Biolabs

Executive Summary

ACM Biolabs is a Singapore-based clinical-stage biotechnology company pioneering a proprietary thermostable polymer-based nanoparticle delivery platform (ATP™). The modular, non-viral system enables the transport of diverse therapeutic payloads including mRNA, oligonucleotides, proteins, and small molecules. The company's pipeline focuses on next-generation vaccines and oncology immunotherapies, with lead programs including a thermostable mRNA rabies vaccine and CpG oligonucleotide-based immunotherapies that modulate the myeloid compartment. By eliminating cold-chain requirements, ATP™ aims to simplify logistics and expand global access to advanced medicines, particularly in underserved regions. The company has raised $15 million to date and is advancing its lead candidates through preclinical and early clinical development. Its thermostable rabies vaccine addresses a significant unmet need in low- and middle-income countries, while the oncology platform targets immunosuppressive myeloid cells in tumors. If successful, ACM Biolabs could disrupt vaccine distribution and cancer immunotherapy paradigms. However, the company remains at an early stage with limited clinical data, and execution risk is moderate. Key near-term catalysts include initial clinical readouts and potential strategic partnerships to validate its platform technology.

Upcoming Catalysts (preview)

• H2 2026Phase 1 data readout for thermostable mRNA rabies vaccine60% success
• Q1 2027IND filing or preclinical data for CpG oncology immunotherapy50% success
• H1 2026Strategic partnership or licensing deal for ATP platform40% success